Who
Carol Gail Ashe
Director
Company insider
Files Form 4 as: Director, Elicio Therapeutics; Director, Aptose Biosciences.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 Jan 2019
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,750 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,750 at $0.00 | filing |
| 19 May 2025filed 20 May 2025 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,900 at $0.00 | filing |
| 21 Nov 2024filed 25 Nov 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 5 Feb 2024filed 7 Feb 2024 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —3,333 at $0.00 | filing |
| 28 Dec 2023filed 29 Dec 2023 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 19 Jan 2023filed 23 Jan 2023 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 18 Jan 2022filed 20 Jan 2022 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 Jan 2021filed 6 Jan 2021 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 Mar 2020filed 13 Mar 2020 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 31 Jan 2020filed 3 Feb 2020 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 2 Jan 2019filed 3 Jan 2019 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.